The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
METACRINE, INC. | COM | 59101E103 | 1,793 | 2,940,503 | SH | SOLE | 0 | 0 | 2,940,503 | ||
ZYMERGEN INC. | COM | 98985X100 | 345 | 119,205 | SH | SOLE | 0 | 0 | 119,205 | ||
KARUNA THERAPEUTICS, INC. | COM | 48576A100 | 369,323 | 2,912,872 | SH | SOLE | 0 | 0 | 2,912,872 | ||
RUBIUS THERAPEUTICS, INC. | COM | 78116T103 | 1,928 | 349,908 | SH | SOLE | 0 | 0 | 349,908 | ||
SINGULAR GENOMICS SYSTEMS, INC. | COM | 82933R100 | 23,971 | 3,798,926 | SH | SOLE | 0 | 0 | 3,798,926 | ||
EQRX, INC. | COM | 26886C107 | 150,065 | 36,335,375 | SH | SOLE | 0 | 0 | 36,335,375 | ||
ERASCA, INC. | COM | 29479A108 | 95,078 | 11,055,554 | SH | SOLE | 0 | 0 | 11,055,554 | ||
VERVE THERAPEUTICS, INC. | COM | 92539P101 | 57,251 | 2,508,809 | SH | SOLE | 0 | 0 | 2,508,809 |